Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

Discover what's behind Pfizer's sharp decline, from post-pandemic revenue drops to halted drug development and regulatory ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, ...

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...

U.S. regulators will no longer approve COVID booster shots for healthy adults and children without new studies, adding a ...

The U.S. FDA approved Novavax's COVID-19 vaccine with conditions, allowing use for people 65 and older and those 12-64 with ...